Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies

Inclusion Criteria:

1. Age ≥ 18 and ≤ 75, regardless of gender.
2. Blood pressure increased seriously in a short time, systolic blood pressure (SBP) > 180 mmHg and (or) diastolic blood pressure (DBP) > 120 mmHg (measured at an intervalof 5 minutes, both blood pressure values should be > 180 / 120 mmHg), accompanied withprogressive target organ damages as below or evidences of other target organ damagecan be confirmed:

• Hypertensive encephalopathy: headache, dizziness, irritability, nausea, vomiting,blurred vision and other symptoms;
• Acute left heart failure: dyspnea, pulmonary rales, edema and other symptoms;
• Unstable angina pectoris: ischemic chest pain with ST-T dynamic changes. Patientswith SBP ≥ 220mmhg and / or DBP ≥ 140mmHg should be considered as hypertensiveemergency;

3. The legal representative and / or patient agree to participate in this clinical trialand sign an informed consent form.

Exclusion Criteria:

1. Patients with arterial dissection, acute hemorrhagic or ischemic stroke, and acutecoronary syndrome in urgent need of surgical or emergency intervention;
2. Patients with severe aortic stenosis or severe mitral stenosis;
3. Patients with obstructive hypertrophic cardiomyopathy;
4. Patients who have used other intravenous antihypertensive drugs within 2 hours beforeentering this study;
5. Patients known to be intolerant or allergic to calcium channel blockers, or allergicto test drug ingredients, or allergic to soy / soy products or egg / egg products;
6. Patients with lipid metabolism defects, such as pathological hyperlipidemia, lipidnephropathy, or acute pancreatitis with hyperlipidemia;
7. Combined with other serious organ injury or serious complications which may affect thelife of the subjects;
8. Patients with a history of mental illness;
9. Patients with known history of alcohol / drug abuse;
10. Those who have participated in other clinical trials and used test drugs 3 monthsbefore the trial;
11. Pregnant and lactating women;
12. Researchers do not consider it appropriate to participate in the clinical trial.